ATE332703T1 - Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung - Google Patents

Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung

Info

Publication number
ATE332703T1
ATE332703T1 AT04713307T AT04713307T ATE332703T1 AT E332703 T1 ATE332703 T1 AT E332703T1 AT 04713307 T AT04713307 T AT 04713307T AT 04713307 T AT04713307 T AT 04713307T AT E332703 T1 ATE332703 T1 AT E332703T1
Authority
AT
Austria
Prior art keywords
wound healing
hsp20
promote wound
reduce scaring
scaring
Prior art date
Application number
AT04713307T
Other languages
English (en)
Inventor
Colleen Brophy
Alyssa Panitch
Catherine Parmiter
Elizabeth Furnish
Padmini Komalavilas
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Application granted granted Critical
Publication of ATE332703T1 publication Critical patent/ATE332703T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
AT04713307T 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung ATE332703T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44895403P 2003-02-21 2003-02-21
US51221103P 2003-10-17 2003-10-17
US53030603P 2003-12-16 2003-12-16

Publications (1)

Publication Number Publication Date
ATE332703T1 true ATE332703T1 (de) 2006-08-15

Family

ID=32931323

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04713307T ATE332703T1 (de) 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
AT06014290T ATE455553T1 (de) 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06014290T ATE455553T1 (de) 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung

Country Status (9)

Country Link
US (3) US8101572B2 (de)
EP (2) EP1594526B1 (de)
AT (2) ATE332703T1 (de)
AU (1) AU2004216241B2 (de)
DE (2) DE602004025300D1 (de)
DK (2) DK1808179T3 (de)
ES (2) ES2338350T3 (de)
PT (1) PT1808179E (de)
WO (1) WO2004075914A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075914A1 (en) 2003-02-21 2004-09-10 Arizona Board Of Regents Methods for promoting wound healing and/or reducing scar formation
WO2005037236A2 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
BRPI0714383A2 (pt) * 2006-07-12 2013-04-30 Univ Arizona mÉtodos para tratar e limitar desordens fibràticas e queloides
CA2898230C (en) * 2007-01-10 2018-04-24 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
BRPI0922448A2 (pt) 2008-12-10 2021-02-17 Purdue Research Foundation inibidor com base em peptídeo penetrante celular de quinases
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US20220127313A1 (en) * 2019-02-12 2022-04-28 Vanderbilt University Polypeptides for restoring endothelial function and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
JP2001278894A (ja) 2000-03-29 2001-10-10 Osamu Ozawa 血液循環障害予防および／または治療用医薬用組成物並びにその有効成分であるペプチド
JP2004503220A (ja) 2000-06-21 2004-02-05 アムジェン　インコーポレイテッド 分泌型結腸上皮間質性−１ポリペプチド、これをコードする核酸、およびその使用
US7135453B2 (en) * 2001-08-23 2006-11-14 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
AU2003260668A1 (en) 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
AU2003269985A1 (en) 2002-08-22 2004-03-11 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University, Office Of T Methods for increasing the rate of heart muscle contraction
WO2004075914A1 (en) 2003-02-21 2004-09-10 Arizona Board Of Regents Methods for promoting wound healing and/or reducing scar formation
WO2005037236A2 (en) 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor

Also Published As

Publication number Publication date
US20120238508A1 (en) 2012-09-20
DK1594526T3 (da) 2006-11-13
DE602004001509D1 (de) 2006-08-24
DK1808179T3 (da) 2010-04-12
EP1808179A2 (de) 2007-07-18
EP1808179B1 (de) 2010-01-20
EP1808179A3 (de) 2007-10-24
DE602004001509T2 (de) 2007-02-15
AU2004216241B2 (en) 2006-12-14
DE602004025300D1 (de) 2010-03-11
US8765673B2 (en) 2014-07-01
WO2004075914A1 (en) 2004-09-10
EP1594526B1 (de) 2006-07-12
US20150072936A1 (en) 2015-03-12
US20100009903A1 (en) 2010-01-14
ES2268631T3 (es) 2007-03-16
PT1808179E (pt) 2010-03-24
ATE455553T1 (de) 2010-02-15
AU2004216241A1 (en) 2004-09-10
ES2338350T3 (es) 2010-05-06
US8101572B2 (en) 2012-01-24
EP1594526A1 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
CY1119127T1 (el) Επιτοποι σκληροστινης
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE60323155D1 (de) Von transthyretin und zur hemmung von transthyretin-fehlfaltung
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
ATE356607T1 (de) Verwendung von nativem zein zur verbesserung des haarzustandes und mittel
ATE484201T1 (de) Verwendung von beta-cryptoxanthin
DK1545587T3 (da) Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
ATE419865T1 (de) Verwendung von protein-kinase-n-beta
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
ATE515268T1 (de) Verwendung von op-1 zur behandlung von knorpeldefekten
DE60335018D1 (de) Mittel zur verhinderung von hautalterung
ATE455553T1 (de) Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE557092T1 (de) Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60323533D1 (de) Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
DE602005026259D1 (de) Kosmetische oder therapeutische verwendung von botulinumtoxin zur verhinderung von haarwuchs
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1594526

Country of ref document: EP